BioCentury
ARTICLE | Company News

Spinraza sales drive Biogen's guidance bump

July 25, 2017 11:53 PM UTC

Biogen Inc. (NASDAQ:BIIB) reported 2Q17 earnings, raised its full-year revenue guidance for 2017 and laid out a five-part growth strategy that emphasizes multiple sclerosis, spinal muscular atrophy (SMA) and neuroscience.

The company said faster-than-expected uptake of Spinraza nusinersen drove the decision to raise its guidance to $11.5-$11.8 billion from $11.1-$11.7 billion. Sales of the drug were $203 million in 2Q17, up from $47.4 million in 1Q17. FDA approved the therapy in December 2016 to treat SMA...

BCIQ Company Profiles

Biogen Inc.